Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2003-7-25
pubmed:abstractText
Tumor directed cytotoxic therapy is one of the major challenges for the success of chemotherapy. In order to accomplish this goal in neuroblastoma, we rationally designed a prodrug of etoposide as substrate for tyrosine hydroxylase, a well established neuroblastoma associated enzyme. Here, we report synthesis and characterization of a 3,4 dihydroxy-phenyl carbamate derivative of etoposide. In order to demonstrate activation by tyrosine hydroxylase, the coding sequence of murine tyrosine hydroxylase was generated by reverse transcriptase-polymerase chain reaction from NXS2 neuroblastoma cells and cloned into the pRSET-A bacterial expression vector. The enzyme was expressed in Escherichia coli, characterized by Western blot and enzymatic activity was demonstrated by conversion of tyrosine into DOPA in the presence of cofactors using reversed phase high-performance liquid chromatography. Under these enzymatic conditions, we demonstrate conversion of 3,4 dihydroxy-phenyl carbamate prodrug into free etoposide. This effect was clearly mediated by the enzyme since bacteria transformed with the empty vector were ineffective of prodrug activation. Furthermore, tyrosine hydroxylase positive cells exposed to the etoposide prodrug were effectively killed in contrast to tyrosine hydroxylase negative controls. These findings demonstrate that etoposide can be designed as a prodrug substrate for tyrosine hydroxylase and thereby establish proof of concept for neuroblastoma directed enzyme prodrug therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0304-3835
pubmed:author
pubmed:issnType
Print
pubmed:day
18
pubmed:volume
197
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
219-24
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12880985-Animals, pubmed-meshheading:12880985-Antineoplastic Agents, Phytogenic, pubmed-meshheading:12880985-Biotransformation, pubmed-meshheading:12880985-Blotting, Western, pubmed-meshheading:12880985-Cell Survival, pubmed-meshheading:12880985-Chromatography, High Pressure Liquid, pubmed-meshheading:12880985-Dihydroxyphenylalanine, pubmed-meshheading:12880985-Drug Design, pubmed-meshheading:12880985-Escherichia coli, pubmed-meshheading:12880985-Etoposide, pubmed-meshheading:12880985-Humans, pubmed-meshheading:12880985-Mice, pubmed-meshheading:12880985-Neuroblastoma, pubmed-meshheading:12880985-Plasmids, pubmed-meshheading:12880985-Prodrugs, pubmed-meshheading:12880985-Substrate Specificity, pubmed-meshheading:12880985-Tumor Cells, Cultured, pubmed-meshheading:12880985-Tyrosine, pubmed-meshheading:12880985-Tyrosine 3-Monooxygenase
pubmed:year
2003
pubmed:articleTitle
Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.
pubmed:affiliation
Charité Childrens Hospital, Experimental Oncology, Humboldt University Augustenburger Platz 1,13353 Berlin, Germany.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't